Q1 EPS Estimates for Cabaletta Bio Raised by HC Wainwright

Cabaletta Bio, Inc. (NASDAQ:CABA) – Research analysts at HC Wainwright raised their Q1 2025 earnings estimates for shares of Cabaletta Bio in a note issued to investors on Tuesday, April 1st. HC Wainwright analyst D. Tsao now anticipates that the company will earn ($0.63) per share for the quarter, up from their prior estimate of ($0.74). HC Wainwright currently has a “Buy” rating and a $25.00 target price on the stock. The consensus estimate for Cabaletta Bio’s current full-year earnings is ($2.34) per share. HC Wainwright also issued estimates for Cabaletta Bio’s Q2 2025 earnings at ($0.63) EPS, Q3 2025 earnings at ($0.65) EPS, Q4 2025 earnings at ($0.60) EPS, FY2025 earnings at ($2.51) EPS, FY2026 earnings at ($2.46) EPS, FY2027 earnings at ($2.45) EPS and FY2028 earnings at ($2.30) EPS.

Cabaletta Bio (NASDAQ:CABA) last released its earnings results on Monday, March 31st. The company reported ($0.65) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.65).

A number of other research analysts have also issued reports on CABA. Morgan Stanley lowered their target price on Cabaletta Bio from $30.00 to $22.00 and set an “overweight” rating on the stock in a report on Tuesday. Evercore ISI cut shares of Cabaletta Bio from an “outperform” rating to an “inline” rating and lowered their price objective for the stock from $15.00 to $6.00 in a research note on Friday, December 20th. Wells Fargo & Company cut their target price on shares of Cabaletta Bio from $6.00 to $3.00 and set an “equal weight” rating for the company in a research note on Tuesday. UBS Group decreased their price target on shares of Cabaletta Bio from $10.00 to $7.00 and set a “buy” rating on the stock in a research report on Tuesday. Finally, Guggenheim reiterated a “buy” rating and set a $23.00 price objective on shares of Cabaletta Bio in a research report on Tuesday. One investment analyst has rated the stock with a hold rating, seven have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, Cabaletta Bio has an average rating of “Buy” and a consensus target price of $21.00.

Cabaletta Bio Stock Performance

CABA opened at $1.11 on Friday. The company has a market capitalization of $56.32 million, a PE ratio of -0.52 and a beta of 2.44. The stock’s fifty day moving average is $1.98 and its 200-day moving average is $2.89. Cabaletta Bio has a one year low of $1.08 and a one year high of $19.04.

Institutional Investors Weigh In On Cabaletta Bio

Hedge funds have recently made changes to their positions in the company. Point72 Asset Management L.P. purchased a new position in Cabaletta Bio during the 3rd quarter worth approximately $3,150,000. Adage Capital Partners GP L.L.C. lifted its holdings in shares of Cabaletta Bio by 19.7% in the fourth quarter. Adage Capital Partners GP L.L.C. now owns 3,634,473 shares of the company’s stock valued at $8,250,000 after purchasing an additional 597,828 shares in the last quarter. Two Sigma Advisers LP boosted its position in shares of Cabaletta Bio by 195.8% in the fourth quarter. Two Sigma Advisers LP now owns 831,900 shares of the company’s stock worth $1,888,000 after buying an additional 550,700 shares during the period. T. Rowe Price Investment Management Inc. grew its holdings in shares of Cabaletta Bio by 10.9% during the fourth quarter. T. Rowe Price Investment Management Inc. now owns 4,074,006 shares of the company’s stock valued at $9,248,000 after buying an additional 400,282 shares in the last quarter. Finally, Two Sigma Investments LP raised its position in Cabaletta Bio by 78.8% during the fourth quarter. Two Sigma Investments LP now owns 751,894 shares of the company’s stock valued at $1,707,000 after buying an additional 331,417 shares during the period.

Cabaletta Bio Company Profile

Cabaletta Bio, Inc, a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. The company's lead product candidate is CABA-201, a fully human anti-CD19 binder for the treatment of Phase 1/2 clinical trials in dermatomyositis, anti-synthetase syndrome, immune-mediated necrotizing myopathy, lupus nephritis, non-renal systemic lupus erythematosus, systemic sclerosis, and generalized myasthenia gravis.